C-terminal FGF23 is a strong predictor of survival in systolic heart failure

Peptides. 2012 Oct;37(2):258-62. doi: 10.1016/j.peptides.2012.08.003. Epub 2012 Aug 10.

Abstract

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone involved in the regulation of phosphate and calcium metabolism. We have evaluated the levels of C-terminal FGF23 (Ct-FGF23) in 73 patients presenting heart failure with reduced ejection fraction (HF-REF) and assess their potential predictive value for long-term survival through a 6 years follow-up. Ct-FGF23 levels were markedly increased in HF-REF. In univariate proportional hazard model, survival was related to glomerular filtration rate (eGFR), intact parathyroid hormone (PTH), B-type natriuretic peptides (BNP) and Ct-FGF23. In a multivariate analysis including age, EF, PTH, BNP, Ct-FGF23, calcium, phosphorus and eGFR levels, Ct-FGF23 is the strongest predictor of long term CV death.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood*
  • Fibroblast Growth Factors / chemistry*
  • Follow-Up Studies
  • Heart Failure, Systolic / blood*
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Survival Rate

Substances

  • FGF23 protein, human
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23